2025年ESMO大会,再次成为全球肿瘤药物研发创新的风向标。在持续重构的研发版图中,ADC与ADC+IO组合疗法演变为炙手可热的黄金赛道,中国Biotech也在这一浪潮中加速崛起,而乐普生物,正在引领这股技术风潮。今年,乐普生物以三项研究入选ESMO,覆盖EGFR ADC+PD-1联合策略与TF新靶点ADC布局,集中展现了从单靶到联合、从单癌种到多领域的体系化创新能力。乐普生物所构建的以ADC为...
Source Link2025年ESMO大会,再次成为全球肿瘤药物研发创新的风向标。在持续重构的研发版图中,ADC与ADC+IO组合疗法演变为炙手可热的黄金赛道,中国Biotech也在这一浪潮中加速崛起,而乐普生物,正在引领这股技术风潮。今年,乐普生物以三项研究入选ESMO,覆盖EGFR ADC+PD-1联合策略与TF新靶点ADC布局,集中展现了从单靶到联合、从单癌种到多领域的体系化创新能力。乐普生物所构建的以ADC为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.